Press Releases MedinCell S.A.

Equities

MEDCL

FR0004065605

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-02-09 am EST			After hours 03:59:59 pm
24.32 ^EUR	+2.36%		24.32	0.00%

Jan. 29	Modest Recovery for Medincell Following Sharp Decline
Jan. 28	Medincell S.A. Reports Sales Results for the Fourth Quarter and Full 2025	CI

Press Releases

Jan. 28	Medincell - UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%)	BU
Jan. 28	UZEDY®: Net Sales Increased from $117M in 2024 to $191M in 2025 (+63%) ; OLANZAPINE LAI: EU Submission Expected in Q2 2026	PU
Jan. 20	Medincell: Half-year Liquidity Contract Statement	BU
Jan. 12	Medincell: Publication of the 2026 Financial Calendar	BU
Dec. 09	Medincell Publishes its Consolidated Half-Year Financial Results	BU
Dec. 09	Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application1 Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults	BU
Dec. 01	Medincell: Videoconference and Publication of Half-year Financial Results, Tuesday, December 9, 2025	BU
Nov. 27	Medincell Management to Present at the 8th Annual Evercore Healthcare Conference and at the Piper Sandler 37th Annual Healthcare Conference	BU
Nov. 24	Medincell Awarded New Grant to Fight Malaria	BU
Nov. 13	Medincell Management to Participate in Fireside Chat at the Jefferies London Healthcare Conference 2025 (London - Nov. 17-20, 2025)	BU
Nov. 11	Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth	BU
Nov. 11	Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth	BU
Nov. 10	Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark	BU
Nov. 10	Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark	BU
Nov. 06	Medincell to Participate in the UBS Global Healthcare Conference (Palm Beach) and the Stifel Healthcare Conference (New-York)	BU
Nov. 05	Medincell: UZEDY® Continues Strong Growth; Teva Setting the Stage for US NDA Submission for Olanzapine LAI in Q4 2025	BU
25-10-22	Medincell to Participate in the 2025 Truist Securities Biopharma Symposium (New-York)	BU
25-10-13	Teva Pharmaceuticals - FDA Approves Expanded Indication for UZEDY Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder	AQ
25-10-10	Medincell: FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder	BU
25-09-23	Teva and Medincell’s Risperidone LAI Approved in Canada as LONGAVO®	BU
25-09-22	Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed	BU
25-09-22	Medincell: New Data Show that UZEDY® Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna®	BU
25-09-17	Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation	BU
25-09-12	MedinCell S A : Inside Information / Other news releases	PU
25-09-12	Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases MedinCell S.A.

Equities

MEDCL

FR0004065605

Pharmaceuticals

Press Releases

Filters